# **Special Issue**

# Prodrug-Based Nanodelivery Strategies

## Message from the Guest Editor

Nanodelivery systems represent a relatively new but rapidly developing science, and they are employed in the delivery of therapeutic agents to specific targeted sites in a controlled manner. Nanomaterials can be well defined as a material, with sizes ranging between 1 and 100 nm, which influences drug delivery to tissue engineering, such as liposomes. Being nano-sized, the liposomes penetrate the tissue system, facilitate easy uptake of the drug by cells, permit efficient drug delivery, and ensure action at the targeted location. Encapsulation of prodrugs in liposomes makes them nanomedicines, which can be used in selective targeting of tumors due to the permeability and

nanomedicines, which can be used in selective targeting of tumors due to the permeability and retention effect, a phenomenon in which nanoparticles can diffuse through relatively large pores in blood vessels and accumulate at tumor sites. Hence, prodrugbased nanodelivery is a prospective approach to increase the selectivity and efficacy of cancer therapy.

## **Guest Editor**

Dr. Yulin Leu

Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan 717, Taiwan

## Deadline for manuscript submissions

closed (30 November 2022)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



## mdpi.com/si/126303

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Editor-in-Chief

## Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

